

## **SUPPLEMENTARY INFORMATION**

### **The hDIS3L2 exonuclease specifies a parallel 3'-5' degradation pathway of human cytoplasmic mRNA**

Michal Lubas<sup>1,2,3,4</sup>, Christian K. Damgaard<sup>2</sup>, Rafal Tomecki<sup>3,4</sup>,  
Dominik Cysewski<sup>3,4</sup>, Torben Heick Jensen<sup>1,2,\*</sup> and Andrzej Dziembowski<sup>3,4\*</sup>

## **INDEX OF SUPPLEMENTARY INFORMATION**

Figure S1

Figure S2

Figure S3

Figure S4

Figure S5

Table S1: Mass spectrometry data – hDIS3L2 coIP

Table S2: Differentially expressed genes in hDIS3L2 knockdown

Table S3: Differentially expressed genes in hXRN1 knockdown

Table S4: Differentially expressed genes in hDIS3L knockdown

Table S5: Differentially expressed genes in hDIS3L2/hXRN1 knockdown

Table S6: Differentially expressed genes in hDIS3L/hXRN1 knockdown

Table S7: Constructs, RNA substrates, siRNAs and oligonucleotides

## Supplemental figure legends

**Figure S1. Multiple sequence alignment of RNase R, RNase II and Dis3 proteins.** (A) RNase R, RNase II, Dis3p, hDIS3, hDIS3L and hDIS3L2 were aligned using PROMALS3D (Materials and Methods). Evolutionarily conserved protein domains are indicated above the sequences. Amino acid residues are colored by percentage identity (blue gradient). The hDIS3L2 specific extension of the CSD1 domain is highlighted in yellow and the RNB active site is marked by a red frame.

(B) Phylogenetic analysis of hDIS3L2, hDIS3L, hDIS3 and their eukaryotic and prokaryotic homologs. Maximum likelihood tree was constructed based on RNB domain alignments. Dis3L2 proteins are widespread in eukaryotes and form a distant lineage from the Dis3 family.

**Figure S2. hDIS3L2 is a processive 3'-5' exonuclease active towards both ss- and ds-RNA.**

(A) SDS-PAGE analysis of recombinant full-length wild-type hDIS3L2 protein (hDIS3L2<sup>WT</sup>) and its variant bearing the D391N mutation within the RNB domain catalytic site (hDIS3L2<sup>mut</sup>). PageRuler<sup>TM</sup> Prestained Protein Ladder (Fermentas) with molecular masses indicated was used as a marker.

(B) Ion exchange chromatography of hDIS3L2<sup>WT</sup>. Indicated fractions of hDIS3L2<sup>WT</sup> were incubated with a fluorescently labeled linear ss17-A<sub>34</sub> RNA substrate (bottom of image). Fractions C3 and C4 were used for the analyses of hDIS3L2 biochemical properties. No activity of hDIS3L2<sup>mut</sup> towards RNA substrate was observed (data not shown).

**(C)** TLC analysis of the RNA degradation capabilities of hDIS3L2<sup>WT</sup> and hDIS3L2<sup>mut</sup> from (A). Single-stranded ss17-A<sub>14</sub> oligoribonucleotide, 3'-end-labeled with [<sup>32</sup>P]pCp, was incubated with equal amounts of hDIS3L2<sup>WT</sup>, hDIS3L2<sup>mut</sup> or hDIS3<sup>WT</sup> (positive control). Sample aliquots were collected at indicated time points and spotted onto a PEI-cellulose TLC plate, which was subsequently developed in the direction shown with the vertical arrow. Positions of substrate and product (pCp) are indicated. pCp-labeled RNAs are substrates of exoribonucleases from the RNaseR family, which accept the 3'-phosphate (Vincent et al. 2006).

**(D)** hDIS3L2 activity is relatively insensitive to the concentration of magnesium or manganese ions, but is inhibited by elevated concentrations of zinc ions. The linear ss17-A<sub>14</sub> RNA substrate was incubated with hDIS3L2<sup>WT</sup> in various buffers, containing magnesium, manganese or zinc cations at different concentrations, as indicated. Reactions were terminated at the indicated time points followed by denaturing PAGE and phosphorimaging.

**(E)** hDIS3L2 displays 3'-5' exoribonuclease activity towards ssRNA. Wild-type hDIS3L2<sup>WT</sup> or hDIS3L2<sup>mut</sup> proteins were incubated in the presence of Mg<sup>2+</sup> ions with 5'-radiolabeled single-stranded 17nt RNA oligonucleotide substrates bearing adenosine extensions of different lengths (A<sub>5</sub> or A<sub>14</sub>), as indicated. Control reactions were performed in the absence of added protein (no protein). Reactions were terminated at the indicated time points and the products were analyzed by 20% acrylamide/7M urea PAGE followed by phosphorimaging.

**(F)** Final reaction products of hDIS3L2 exoribonucleolytic degradation are shorter than those generated by the hDIS3 enzyme. Reactions were carried

out as in (E) using single-stranded ss17-A<sub>14</sub> ssRNA substrate. Positions of 3–5 nt-long degradation products are marked with arrows.

**(G)** hDIS3L2 and hDIS3 display similar activities against ssRNA. hDIS3<sup>WT</sup>, hDIS3L2<sup>WT</sup> or hDIS3L2<sup>mut</sup> proteins were incubated with single-stranded ss17-A<sub>5</sub> RNA oligonucleotide substrates as in (E), but the reactions were terminated at earlier time points, as indicated.

**(H)** hDIS3L2 is active towards dsRNA. RNase assays were performed as in (E), but using 5′radiolabeled partially structured double-stranded 17nt RNA substrates in which the longer (labeled) oligoribonucleotide possessed 3′ss oligoadenosine overhangs of different length (A<sub>5</sub> or A<sub>14</sub>) as indicated.

**(I)** hDIS3L2 does not display endoribonucleolytic activity. A 5′-labelled and circularized ss17-A<sub>14</sub> RNA substrate was incubated with hDIS3L2<sup>WT</sup> in various buffers containing magnesium, manganese or zinc cations and at different concentrations as indicated. Reaction products were analyzed as in (D).

**(J)** hDIS3L2 does not display 5′-3′ exo- or endo-ribonucleolytic activity. RNase assays were conducted for 90 min using hDIS3L2<sup>WT</sup> or hDIS3L2<sup>mut</sup> in a buffer containing Mn<sup>2+</sup> and 5′radiolabeled RNA substrate blocked at its 3′end by two deoxythymidine nucleotides to prevent 3′-5′ exonucleolysis. Reaction products were analyzed as in (D).

**Figure S3. Increased PB numbers upon hDIS3L2 depletion.**

**(A)** Western blotting validation of hDIS3L2 and hXRN1 levels in EGFP (control), hDIS3L, hDIS3L2, hXRN1, hXRN1/hDIS3L and hXRN1/hDIS3L2 siRNA-treated HeLa cells used for PB analysis. Membranes were probed with the indicated antibodies. Actin was probed as a loading control.

**(B)** RT-qPCR validation of hDIS3L mRNA levels in EGFP (control), hDIS3L and hDIS3L/hXRN1 siRNA-treated HeLa cells used for PB analysis. PCR primers (Table S1) spanned an exon-exon junction of the hDIS3L mRNA. A U6-directed amplicon was used for normalization.

**(C)** Subcellular localization of hDCP1a (left) and hXRN1 (right) in HeLa cells treated with siRNAs against EGFP (control) or hDIS3L2. Proteins were visualized by fluorescence microscopy using 63X oil-immersion objective. Nuclei were stained with DAPI and merged with the localization of the respective proteins.

**Figure S4. Validation of hDIS3L2, hXRN1 and hDIS3L depletions in HeLa cells used for RNA seq analysis.**

(A) Western blotting validation of hDIS3L2 and hXRN1 protein levels in EGFP (control), hDIS3L, hDIS3L2, hXRN1, hXRN1/hDIS3L and hXRN1/hDIS3L2 siRNA-treated HeLa cells. Bars represent mean values of two biological replicates for each knockdown condition. Membranes were probed with the indicated antibodies. ImageJ was used for quantification.

(B) RNA-seq validation of hDIS3L mRNA levels in EGFP (control), hDIS3L, hDIS3L2, hXRN1, hXRN1/hDIS3L and hXRN1/hDIS3L2 siRNA-treated cells. Bars represent mean number of sequence reads in two biological replicates. The number of reads was normalized to the library size.

**Figure S5. Correlation, quantification and verification of affected transcripts.**

**(A)** Hierarchical clustering heatmap showing 200 differentially expressed

genes (DEGs) of the highest confidence (adjusted p-value with the Benjamin-Hochberg correction ( $p_{adj}$ )). The correlation dendrogram (top panel) indicates the relationship of gene-expression levels between the indicated conditions and replicates.

**(B)** Venn diagrams representing the quantity of indicated transcript groups and their overlap. Diagrams show all- (left), upregulated- (middle) ( $\geq 2$ -fold changed,  $p_{adj} \leq 0.05$ ) and downregulated- (right) ( $\leq 2$ -fold changed,  $p_{adj} \leq 0.05$ ) RNAs.

**(C)** DESeq scatter plots showing pair-wise comparisons of transcript levels between the indicated samples versus the control. Each dot represents the mean expression value of 2 replicates. DEGs are indicated in red.


**(D)** qRT-PCR validation of RNAseq data showing selected upregulated mRNAs from all single depletions. Each PCR reaction was performed in triplicate from two independent biological samples. Error bars calculated as standard error of the mean.

**(E)** qRT-PCR validation of selected mRNAs upregulated upon hDIS3L2 depletion using two different siRNAs (upper right: western blotting validation of depletions). qPCR data was normalized to levels of total RNA. Each PCR reaction was performed in triplicate and a representative experiment is shown. Western blotting analysis was performed as in S4A. The hDIS3L2#1 siRNA was used elsewhere in this study.

**(F)** Graphs representing highly enriched GO terms among non-redundant, upregulated mRNAs from hDIS3L2 (cellular component terms) and hXRN1 (biological and molecular function terms) knockdown samples clustered using DAVID. Only the most enriched clusters for each condition are shown.


Barplots represent percentage of GO terms within nonredundant upregulated mRNAs ( $-\log(\text{pvalue})$ ).

Figure S1A






**Figure S1B**




**Figure S2**




**Figure S2**


**(E)**



**(F)**




**(G)**




**Figure S2**


**(H)**



**(I)**




**(J)**



**Figure S3**


**(A)**

**hDIS3L2 and hXRN1 knockdown validation**




**(B)**

**hDIS3L2 knockdown validation**




**(C)**



**Figure S4**

**(A)**

hDIS3L2 and hXRN1 knockdown validation (average fold change western blotting analysis)



**(B)**

hDIS3L knockdown validation (average change in RNAseq libraries)





Figure S5

(A)


Hierarchical clustering heatmap



# Figure S5

(B)

Differentially expressed genes in a given sample compared to control





# Figure S5

(C)

Pair-wise comparisons of gene expression of knockdowns versus control





Figure S5

(D)


RNAseq validation qPCR

upregulated



**Figure S5**

**(E)**



**(F)**

